In Japan, long-term business relationships are essential to business success. This presents a real challenge for international pharmaceutical and healthcare companies entering Japan.Japanese business culture places greater significance on relationships over business transactions. While in Western business, rapid business deals…
HOME > BUSINESS
BUSINESS
- Sumitomo Dainippon, Carna Bio Cut Deal on Kinase Inhibitor Research in Psychiatry/Neurology
March 28, 2018
- Enfortumab Vedotin Gets FDA Breakthrough Status in Urothelial Cancer: Astellas/Seattle Genetics
March 28, 2018
- Zeria Obtains Japan Rights to Veltassa from Vifor Pharma
March 28, 2018
- Mitsubishi Tanabe Explores Creation of Drug Safety Info. Database with Drug Makers: President
March 28, 2018
- Daiichi Sankyo to Launch Open Innovation Research on Novel Cancer Hyperthermia Therapy with Academia, Venture Capital
March 28, 2018
- Opdivo Gains Label Expansion in South Korea: Ono
March 27, 2018
- Shionogi, Kyoto Univ. Ink Research Collaboration for Psychiatric Disorders
March 27, 2018
- Asahi Kasei in Licensing Pact with RaQualia to Begin Preclinical Development for Novel Neuropathic Pain Candidate
March 27, 2018
- Stem Cell Therapy Alofisel Wins European Approval: Takeda
March 27, 2018
- JCR Shooting for Big Chunk of 900 Billion Yen Global Lysosome Storage Disease Market with J-Brain Cargo
March 27, 2018
- Mitsubishi Tanabe Aims to Attain Efficiency in Clinical Trials through Full-Fledged Use of Hitachi’s AI Technology
March 27, 2018
- Japan Approves 1st Herceptin Biosimilar for Gastric Cancer
March 26, 2018
- Shionogi Partners with CARB-X to Fight CRE Superbug
March 23, 2018
- Thomas-Peter Hausner Named Next President of Bayer Holdings Japan
March 23, 2018
- Lilly Japan Sales Up 7% in 2017, Upbeat Biz Fueled by Global Simultaneous Development
March 23, 2018
- Eldecalcitol NDA Accepted in China: Chugai
March 23, 2018
- J-TEC’s Cell Sheet JACE Filed for Epidermolysis Bullosa
March 23, 2018
- EA Pharma, Irish Cosmo Technologies Hook Up on Colonoscopy Products
March 23, 2018
- Single Generic Pricing Rule Will Accelerate Unreasonable Price Raises: Sawai Chief
March 22, 2018
- Takeda Global Headquarters Completed
March 22, 2018
ページ
The pharmaceutical industry has called for abolishing “off-year” drug price revisions in the run-up to the formulation of the 2024 Basic Policy on Economic and Fiscal Management and Reform (honebuto) later in June. It appears that its lobbying efforts have…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…